Evidence map›Paper›PMID 26237164›Full record

ArticleBone marrow transplantation2015

A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.

P Satwani, K W Ahn, J Carreras, H Abdel-Azim, M S Cairo, A Cashen, A I Chen, J B Cohen, L J Costa, C Dandoy and 26 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Functional status at listing predicts waitlist and posttransplant mortality in pediatric liver transplant candidates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 20 institutions in 8 countries.

P SatwaniDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, NY, USA.
K W AhnCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.
J CarrerasCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.
H Abdel-AzimDivision of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
M S CairoPediatric Hematology/Oncology and Stem Cell Transplantation, New York Medical College, New York, NY, USA.
A CashenDivision of Oncology, Washington University School of Medicine, St Louis, MO, USA.
A I ChenOregon Health and Science University, Portland, OR, USA.
J B CohenDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
L J CostaDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
C DandoyCincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
T S FenskeDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
C O FreytesSouth Texas Veterans Health Care System and University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
S GangulyBlood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
R P GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
N GhoshDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
M S HertzbergDepartment of Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
R J HayashiDivision of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, MO, USA.
R T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
A S KanateOsborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
A KeatingDepartment of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
M A Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
H M LazarusSeidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
D I MarksPediatric Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK.
T NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
R F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
T D PrestidgeBlood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
J M RolonBone Marrow Transplante Unit, FUNDALEU, Buenos Aires, Argentina.
B N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
J M VoseDepartment of Internal Medicine, The Nebraska Medical Center, Omaha, NE, USA.
W A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
D J InwardsDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
V BachanovaBone and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
S M SmithSection of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
D G MaloneyFred Hutchinson Cancer Research Center, Seattle, WA, USA.
A SuredaServei d'Hematologia, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
M HamadaniCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · USMoffitt Cancer Center · USWashington University in St. Louis · USBaylor College of Medicine · USCarolinas Healthcare System · USChildren's Hospital of Los Angeles · USCincinnati Children's Hospital Medical Center · USColumbia University Irving Medical Center · USEmory University · USFred Hutch Cancer Center · USFundación para la Investigación, Docencia y Prevención del Cáncer · ARImperial College London · GBInstitut Català d'Oncologia · ESKarolinska Institutet · SEMayo Clinic in Arizona · USNebraska Medical Center · USNew York Medical College · USOregon Health & Science University · USPrince of Wales Hospital · AUPrincess Margaret Cancer Centre · CA

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS U24 CA076518NCI NIH HHS U24-CA076518NHLBI NIH HHS 5U10HL069294NHLBI NIH HHS U10 HL069294PHS HHS HHSH250201200016C
6 · The paper itself

Abstract

Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age <30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995 and 2010. The probabilities of PFS at 1, 5 and 10 years were 66% (95% confidence interval (CI): 62-70), 52% (95% CI: 48-57) and 47% (95% CI: 42-51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score ⩾90, no extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with time from diagnosis to first relapse of <1 year had a significantly inferior PFS. A prognostic model for PFS was developed that stratified patients into low-, intermediate- and high-risk groups, predicting for 5-year PFS probabilities of 72% (95% CI: 64-80), 53% (95% CI: 47-59) and 23% (95% CI: 9-36), respectively. This large study identifies a group of CAYA patients with relapsed/refractory HL who are at high risk of progression after AutoHCT. Such patients should be targeted for novel therapeutic and/or maintenance approaches post-AutoHCT.

Indexed as

Hematopoietic Stem Cell TransplantationModels, TheoreticalAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsCause of DeathChildChild, PreschoolCombined Modality TherapyDisease-Free SurvivalDisease ProgressionFemaleFollow-Up StudiesHodgkin DiseaseHumansMale

Identifiers

PMID26237164
PMCPMC4633349
OpenAlexW1076230489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.